通过准迷走神经来治疗心力衰竭
Francesco Gentile1,2, Giulia Orlando3, Sabrina Montuoro3
1Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà 33, 56127, Pisa, Italy. frage1993@gmail.com.
Heart failure reviews
|August 8, 2024
概括
慢性心力衰竭涉及自主失衡,降低了副交感活动,恶化了结果. 这篇评论探讨了针对心力衰竭治疗的迷走神经的神经调节策略.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 身体生理学 身体生理学
背景情况:
- 自主性失衡的特征是同情神经活动增加和副同情神经活动减少,与慢性心力衰竭的进展和不良结果有关.
- 降低心率变化和巴罗反射灵敏度表明阴道功能障碍,即使在当代治疗中,在心力衰竭患者中也具有预后价值.
研究的目的:
- 为了审查副交感神经系统在慢性心力衰竭中的作用.
- 描述心力衰竭中副交感刺激的病理生理基础,评估方法和治疗策略.
主要方法:
- 在慢性心力衰竭中对副交感神经系统功能研究的文献综述.
- 分析当前和新兴的神经调节策略,包括药理学和生物电子方法.
主要成果:
- 副交感功能障碍是慢性心力衰竭病理生理学和预后的一个重要因素.
- 目前针对迷走神经的神经调节策略显示出混合的结果,需要进一步的研究.
结论:
- 副交感刺激为慢性心力衰竭提供了潜在的治疗途径.
- 进一步研究基于药物和基于设备的神经刺激对于优化治疗疗效和患者结果至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147


